B
Bullisch
Bullisch · 25%EVAX
$3.29
Szenariopreis
$2.950
+0.203 (+6.88%)Zum Schluss
Loading chart…
- Hoch
- 3.210
- Eröffnung
- 2.770
- Volumengewichteter Durchschnittskurs
- 2.96
- Volumen
- 182.86K
- Marktkap.
- 15.53M
- Tief
- 2.710
- Umsatz
- 540.66K
- EV/EBITDA, TTM
- -3.87
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
KI-Analyse of Evaxion A/S (EVAX)
KaufenEvaxion Biotech appears to be a good buy right now, with the current price at $2.95 and a recent RSI of 47.92 indicating that the stock is not overbought. The company has shown significant progress in its clinical trials, with a 75% objective response rate for its EVX-01 vaccine, which is a strong indicator of its potential success in the market. However, investors should be cautious of the high net loss of $3.7 million reported for Q2 2026, which poses a risk to the company's financial stability.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Evaxion A/S (EVAX) beträgt 3.57, verglichen mit dem 5-Jahres-Durchschnitt von -3.33.
Alphio-AI-Kursszenarien für EVAX
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
8.511-06NewsfilterEvaxion Unveils Strong Immune Responses from EVX-01 Vaccine Data
- 9.011-03Newsfilter
Evaxion Presents Phase 2 Data for EVX-01 at SITC 2026
- 8.510-30Newsfilter
Evaxion Wins 2026 International Prix Galien Award for AI-Immunology™
- 9.010-23Newsfilter
Three-Year Clinical Data for EVX-01 Released
2.010-19stocktwitsIntel Shares Rise 4% After JPMorgan Upgrade to Neutral
EVAX FAQ – beantwortet von Alphio AI
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections. It operates in the Healthcare sector.
Evaxion Biotech appears to be a good buy right now, with the current price at $2.95 and a recent RSI of 47.92 indicating that the stock is not overbought. The company has shown significant progress in its clinical trials, with a 75% objective response rate for its EVX-01 vaccine, which is a strong indicator of its potential success in the market. However, investors should be cautious of the high net loss of $3.7 million reported for Q2 2026, which poses a risk to the company's financial stability.
Community
Mehr ↗
$INTC, $EVAX, and $RCAT stocks moved higher in premarket trading. What's driving the rally? $INTC $EVAX $RCAT
Mehr anzeigenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.